Intimal proliferation in coronary arteries of normolipidaemic pigs with a fixed stenosis: the effects of fish oil

Antiatherosclerotic potency of high density lipoprotein of different origins: a review and some new findings

The antiatherosclerotic potency of isolated high density lipoproteins (HDL) of different origins was investigated in three experimental models: (1) isolated HDL were injected into cholesterol-rich fed rabbits; (2) the effect of HDL on the intracellular level of free and esterified cholesterol as well as on proliferation of smooth muscle cells and fibroblasts was investigated in cell cultures; and (3) we studied the influence of isolated HDL fractions on thromboxane (TXB2) formation in clotting whole blood with different cholesterol content.

Age-response effectiveness of gallopamil for the treatment of myocardial exertional ischemia. A medium-term randomized cross-over double-blind placebo-controlled trial

We evaluated the efficacy and safety of gallopamil 150 mg daily in middle-aged and elderly patients with stable exertional ischemia, using a medium-term randomized double-blind cross-over placebo-controlled trial. Twenty middle-aged patients (52.8 +/- 6 years; range 38-61 years) and 14 elderly patients (67.4 +/- 2.8 years; range 65-73 years) with stable exertional ischemia underwent a bicycle exercise test. After a run-in period, both groups received treatment with either placebo or gallopamil 50 mg tid for 28 days. At the end of this time, each patient crossed over to the alternate regimen. Gallopamil significantly reduced heart rate, blood pressure and rate pressure product (from 15.37 +/- 2.7 to 13.65 +/- 4.16 U x 10(-3); p < 0.01) in elderly patients at submaximal exercise, but had no effect in middle-aged patients (from 14.52 +/- 4.45 to 13.49 +/- 3.77 U x 10(-3); p = NS). At peak exercise, none of the hemodynamic parameters was modified with gallopamil in either group. At peak exercise, both middle-aged and elderly patients achieved rate-pressure products similar to those reached during placebo at higher work loads. Exercise duration and maximal work load significantly increased in both groups. Electrocardiographic signs of ischemia were favorably influenced by gallopamil in both groups (from 1.39 +/- 0.5 mm to 0.76 +/- 0.73 mm; p < 0.001 in the middle-aged patients and from 1.5 +/- 0.34 mm to 1 +/- 0.76 mm; p < 0.01 in the elderly patients).(ABSTRACT TRUNCATED AT 250 WORDS)

Dietary n - 3 polyunsaturated fatty acids modify Syrian hamster platelet and macrophage phospholipid fatty acyl composition and eicosanoid synthesis: a controlled study

The aim of this study was to determine the effects of varying intakes of dietary n - 3 polyunsaturated fatty acids (PUFA) on the fatty acyl composition and arachidonic acid metabolite synthesis of platelets and macrophages in Syrian hamsters consuming diets that were strictly controlled for n - 6 PUFA content. Animals consumed highly controlled diets which were not supplemented with n - 3 PUFA (control) or supplemented with 0.4%, 0.8% or 2% (w/w) n - 3 fatty acids. The content of n - 3 PUFA in cellular phospholipids increased progressively with the intake of n - 3 PUFA, while n - 6 PUFA, including arachidonic acid, decreased despite the constant intake of 18:2(n - 6); this latter effect was more substantial in macrophages than in platelets. The synthesis by stimulated macrophages of prostaglandin E2, 6-keto-prostaglandin F1 alpha, thromboxane B2 and 11- and 15-hydroxyeicosatetraenoic acids decreased with the intake of 0.8% n - 3 PUFA to 30-50% of the control values. Little effect of diets on platelet aggregation and eicosanoid synthesis was observed reflecting the limited effect on platelet arachidonic acid content. The synthesis of 12-hydroxyeicosapentaenoic acid by stimulated platelets increased with n - 3 PUFA consumption in a dose-dependent fashion. Circulating triacylglycerols and HDL-cholesterol were decreased only in animals consuming 2% n - 3 PUFA. The strict control of n - 6 PUFA intake allows the determination of the effects of n - 3 PUFA intake on the measured parameters without confounding effects of other dietary lipids.

Is the antiatherosclerotic potency of HDL modulated by the origin of HDL?

Different HDL preparations from rabbit blood were injected intravenously (10 mg HDL protein/injection and animal) into cholesterol fed rabbits twice a week for 8 weeks. The composition of the used high density lipoprotein (HDL) was modified by dietary pretreatment. HDL-1 was taken from rabbits after 8 weeks pellet diet, HDL-2 after 8 weeks fish-oil rich diet and HDL-3 after 8 weeks of cholesterol rich diet. The animals treated with HDL-1 and HDL-2 had a significantly smaller area of intima covered with fatty streaks than the control animals (injection of saline instead of HDL). The injection of HDL-3 was without influence. These differences were correlated with changes in the level of free and esterified cholesterol (FC and CE) in kidney, liver and aorta of the rabbits, but not with the level of cholesterol in the serum lipoproteins. We investigated simultaneously the influence of the different HDL preparations on the cholesterol content in rabbit skin fibroblasts (RSF), rabbit smooth muscle cells (SMC) and human hepatoma cell line Hep G2. Additionally the influence on the proliferation of SMC was studied. HDL-1 diminished the level of FC in cholesterol enriched RSF and rabbit SMC, whereas both other HDL preparations had no effect. The level of FC in Hep G2 was not influenced. HDL-1 and HDL-3 stimulated the proliferation of rabbit SMC, whereas HDL-2 had no such influence. The data support the antiatherosclerotic role of HDL injections in cholesterol fed rabbits, but the composition of the used HDL seems to modify this influence, probably by different effects on the biochemical changes induced by the HDL.